On April 6, 2026, Affinia Therapeutics announced that Health Canada approved the company to begin its UPBEAT clinical trial, a Phase 1/2 study testing AFTX-201, a gene therapy designed to treat BAG3-associated dilated cardiomyopathy (BAG3 DCM). The U.S. FDA had already cleared the same trial in February 2026, and the agency granted Fast Track designation in March.
Affinia Therapeutics estimates that more than 70,000 people are living with BAG3 DCM across the U.S., Canada, the European Union and the U.K. There are currently no treatments that address the genetic cause of the disease. Every existing option manages symptoms. AFTX-201 is 1 of 3 gene therapies now in trials that try a different approach, adding back a working copy of the BAG3 gene.
15 Years from Gene Discovery to First Patient
The path from discovering BAG3's role in heart disease to beginning a clinical trial took about 15 years of research across multiple institutions and continents.
The story begins in 2006, when Patrick Ellinor and colleagues used genome-wide linkage analysis in affected families to map a new genetic region on chromosome 10 linked to dilated cardiomyopathy, heart muscle scarring and sudden death (Ellinor et al., 2006). At the time, researchers did not yet know which specific gene in the region was responsible.
That answer came in 2011. Norton et al. used copy number variation analysis and exome sequencing to identify a deletion mutation in the BAG3 gene that appeared consistently in family members with heritable dilated cardiomyopathy (Norton et al., 2011). The same year, Villard and colleagues published a separate genome-wide association study linking BAG3 variants to heart failure from DCM (Villard et al., 2011). These two studies, published independently, confirmed that BAG3 was a major genetic cause of the disease.
Over the next decade, research teams in the U.S., Europe, and Japan worked to understand exactly how BAG3 mutations damage the heart. The picture that emerged: BAG3 protein acts like a quality control system inside heart muscle cells. It helps clear out damaged and misfolded proteins, maintaining the structural integrity of the sarcomere (the contractile unit of heart muscle). When the gene is mutated and the protein is deficient, damaged proteins accumulate, and the heart muscle gradually weakens.
A 2021 study published in Nature Communications found that raising BAG3 levels with adeno-associated virus (AAV9) gene therapy in mice with heart failure fully restored the heart muscle's force-generating capacity and its protein turnover after 4 weeks (Martin et al., 2021). This was early evidence that adding BAG3 back could reverse the damage in mice rather than only slow it. Results in mice do not always carry over to people.
How Common Is BAG3 DCM?
Dilated cardiomyopathy overall affects about 1 in 250 people worldwide, making it one of the more common forms of heart disease. Within that population, BAG3 mutations account for roughly 2-4% of cases, making it the second most common genetic cause of DCM after titin mutations (Dominguez et al., 2018).
The clinical profile of BAG3 DCM is distinct from other genetic cardiomyopathies. Disease penetrance reaches about 80% in people over age 40 who carry the mutation. Men tend to be diagnosed earlier (average age 35) than women (average age 41). Unlike some other genetic forms like LMNA-related DCM, serious ventricular arrhythmias are relatively uncommon at about 1% per year. The primary clinical problem is progressive heart failure, with transplant, LVAD, or heart failure death occurring at 4.3% annually (Dominguez et al., 2018).
Latest for Dilated Cardiomyopathy
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse…ClinicalTrials.gov
Free email alert
Want the next Dilated Cardiomyopathy update without checking back?
We email you when a new Dilated Cardiomyopathy trial opens or an FDA decision comes out.
You'll get trial alerts and disease updates for Dilated Cardiomyopathy, and you can turn either off anytime. We never share your email. Privacy policy
Three BAG3 Gene Therapy Trials, Three Delivery Approaches
Affinia Therapeutics is not the only company developing a gene therapy for BAG3 DCM. Rocket Pharmaceuticals received FDA clearance for its own program, RP-A701, in June 2025. On August 10, 2026, Rocket said patient screening and enrollment had begun, with first dosing expected in the second half of 2026. Alexion, AstraZeneca's rare disease unit, has a third trial that ClinicalTrials.gov lists as starting in October 2025, earlier than both. Each program uses a different viral shell, or capsid, to carry the gene into the heart, which gives patients more than one trial to ask about.
Alexion (AstraZeneca): ALXN2350
ALXN2350 carries the BAG3 gene in an AAV9 capsid and is given as a single intravenous infusion. ClinicalTrials.gov lists its Phase 1/2 trial (NCT07218887) as recruiting, with a start date of October 24, 2025, about 6 participants planned and sites in the US, Italy, Spain and the UK. It is open to adults 18 to 70 with a disease-causing BAG3 variant, an ejection fraction above 15% and no higher than 45%, and NYHA Class I to III heart failure. People with antibodies to AAV9 cannot join. No results have been posted for it.
Affinia Therapeutics: AFTX-201 (UPBEAT Trial)
Affinia was founded in 2019 (originally as TDTx Inc.) based on capsid engineering research from Luk Vandenberghe's laboratory at Harvard. The company has raised $241 million in total funding, including a $40 million Series C round in October 2025 led by New Enterprise Associates with strategic investment from Eli Lilly (Affinia Therapeutics, 2025).
AFTX-201 uses a proprietary engineered AAV capsid designed specifically for heart muscle delivery. According to Affinia, the capsid achieves cardiac transduction at doses 5 to 10 times lower than conventional AAV serotypes like AAV9 or AAVrh74. Affinia says a lower dose could matter because high-dose AAV gene therapies have been associated with serious immune responses and liver toxicity in other disease programs. No study has compared the safety of AFTX-201 with the other 2 BAG3 programs.
The UPBEAT trial is a multicenter, open-label Phase 1/2 study enrolling about 22 adults with a truncating BAG3 mutation. The age range differs by source. Affinia's April 6, 2026 release said participants should be 18 to 55, while the ClinicalTrials.gov record (NCT07426419), last updated October 21, 2026, lists ages 18 to 70. That record also asks for a left ventricular ejection fraction below 50%, New York Heart Association Class II or III heart failure and a body weight of 120kg or less, so ask the study team which age limit applies today. People with a heart transplant or an LVAD cannot join. Participants receive a single intravenous infusion of AFTX-201. The primary endpoint is safety over 12 months, with secondary endpoints that include ejection fraction, exercise capacity, symptoms and blood markers of the gene's effect. Sites listed in October 2026 are in Miami, Kansas City, New York, Houston and Montreal.
Rocket Pharmaceuticals: RP-A701
Rocket Pharmaceuticals uses a naturally occurring capsid, an AAVrh.74 vector, to deliver the BAG3 gene. The company received FDA IND clearance in June 2025 and has described RP-A701 as a first-in-class treatment for BAG3 DCM (Rocket Pharmaceuticals, 2025). Its Phase 1 trial (NCT07137338) is listed on ClinicalTrials.gov as recruiting at UC San Diego, Mayo Clinic in Rochester and the Medical University of South Carolina. It is for adults 18 to 65 who have had an implanted defibrillator (ICD) for at least 3 months and mild to moderate loss of pumping function, an ejection fraction of 25-45%, with NYHA Class II or III symptoms.
The programs differ in capsid technology, dosing strategy and the first patients they enroll. None of the 3 companies has reported results in people yet, so there is no way to compare how well or how safely they work.
What the Regulatory Milestones Mean
AFTX-201 went from FDA clearance of its trial to clearance for the same trial in a second country in about 2 months. Here is the timeline:
February 2026: FDA accepts IND application for the UPBEAT trial. March 2026: FDA grants Fast Track designation, which provides more frequent regulatory meetings and the potential for priority review if the therapy reaches the approval stage. April 2026: Health Canada authorizes the UPBEAT trial to begin enrolling patients in Canada. July 2026: Affinia announces FDA Orphan Drug designation for AFTX-201 and says UPBEAT is recruiting at several sites in the U.S. and Canada. Affinia says it also holds orphan designation in the European Union.
The FDA grants Fast Track to drugs meant to treat a serious condition and fill an unmet medical need. It gives the company more frequent meetings with the agency and the option to submit an application in parts. It does not guarantee approval.
What This Means for Patients and Families
If you or a family member has been diagnosed with BAG3-associated dilated cardiomyopathy, the UPBEAT trial is now actively enrolling. Eligibility requires a genetically confirmed truncating BAG3 mutation, while the Rocket and Alexion trials list any disease-causing or likely disease-causing BAG3 variant. If you have not had genetic testing, that would be the first step. Many cardiology centers can order a cardiomyopathy gene panel, and some patient advocacy organizations offer guidance on access.
A few important things to keep in mind: this is a Phase 1/2 trial, which means the primary goal is to establish that the therapy is safe. Any efficacy data will take time. ClinicalTrials.gov lists an estimated primary completion date of December 2028. Gene therapy is also a one-time treatment by design, which means the decision to enroll carries long-term considerations that are worth discussing with your care team.
For the broader dilated cardiomyopathy community, these trials could serve as a proof of concept for something larger. If gene therapy works for BAG3 DCM, the same approach could potentially be adapted for other genetic forms of heart failure caused by mutations in titin, lamin A/C, and other genes. That is not a guarantee, but the scientific groundwork is being laid right now.
